LONDON--Allied-Bristol Life Sciences, LLC, a biopharmaceutical enterprise jointly owned between Allied Minds (ALM.LN) and Bristol-Myers Squibb Company (BMY), on Thursday announced that it has entered into a worldwide licensing agreement with Yale University for a platform technology and associated lead molecules that will be further developed to treat diseases such as prostate cancer.

Allied Minds shares at 0813 GMT up 20 pence, or 4.65%, at 450 pence.

 

-Write to Jana Simmons at jana.simmons@wsj.com

 

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

(END) Dow Jones Newswires

August 27, 2015 04:30 ET (08:30 GMT)

Copyright (c) 2015 Dow Jones & Company, Inc.
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Bristol Myers Squibb Charts.
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Bristol Myers Squibb Charts.